Three Lots of Imovax Rabies Pre-Exposure Vaccine Voluntarily Recalled
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Three Lots of Imovax Rabies Pre-Exposure Vaccine Voluntarily Recalled

SWIFTWATER, PA -- July 27, 2000 -- Aventis Pasteur Inc. announced today that, as a precautionary measure, they are voluntarily recalling three lots of a rabies vaccine that is used for pre-exposure immunization.

This vaccine is used by individuals who are at high risk of exposure to rabies. These individuals include veterinarians, animal handlers, spelunkers, certain laboratory workers as well as people traveling to other parts of the world where rabies is endemic.

This is not the same vaccine that is used when an individual is bitten by an animal suspected of carrying rabies.

The vaccine being recalled is Imovax® Rabies ID, lot numbers P0313-3, P0030-2 and N1204-2. It is being recalled because results from routine stability testing conducted by the company detected that the potency of one lot had fallen below specification prior to the product’s expiration date.The other two related lots are being recalled as a precautionary measure.

Aventis Pasteur recommends that individuals who received pre-exposure immunization to rabies should contact their health care provider to determine if they should be re-immunized.

"There is no threat to health from receiving this vaccine. It is an issue of level of protection for individuals at high risk of exposure to rabies," said Frederick L. Ruben, M.D., Director, Scientific & Medical Affairs at Aventis Pasteur. "Because standard protocol for individuals who are exposed to rabies and who received pre-exposure immunization is for subsequent immunization with intramuscular (IM) rabies vaccine, we believe these individuals will develop sufficient antibodies for protection against disease even if they had been immunized with subpotent Imovax® Rabies ID."

The company is contacting all customers and distributors who received the recalled lots and will replace the vaccine at no charge to health care providers. The lots were first shipped in September 1998.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities